Anti-VEGF Receptor 3 抗体 (ab154079)
Key features and details
- Rabbit polyclonal to VEGF Receptor 3
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-VEGF Receptor 3 antibody
VEGF Receptor 3 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to VEGF Receptor 3 -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details -
種交差性
交差種: Human -
免疫原
Recombinant fragment corresponding to a region within amino acids 1131-1352 of Human VEGF Receptor 3.
-
ポジティブ･コントロール
- 293T, A431, H1299, HeLa, HepG2, Molt-4 and Raji cell lysates.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 10% Glycerol (glycerin, glycerine) -
Concentration information loading... -
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab154079の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB |
1/500 - 1/3000. Predicted molecular weight: 153 kDa.
|
| 特記事項 |
|---|
|
WB
1/500 - 1/3000. Predicted molecular weight: 153 kDa. |
ターゲット情報
-
機能
Receptor for VEGFC. Has a tyrosine-protein kinase activity. -
組織特異性
Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain. -
関連疾患
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue. -
配列類似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 2324 Human
- Omim: 136352 Human
- SwissProt: P35916 Human
- Unigene: 646917 Human
-
別名
- EC 2.7.10.1 antibody
- flt 4 antibody
- FLT-4 antibody
see all
画像
-
Western blot - Anti-VEGF Receptor 3 antibody (ab154079)Anti-VEGF Receptor 3 antibody (ab154079) at 1/1000 dilution + MOLT4 whole cell lysate at 30 µg
Predicted band size: 153 kDa
5% SDS PAGE
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (3)
ab154079 は 3 報の論文で使用されています。
- Meçe O et al. Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nat Commun 13:2760 (2022). PubMed: 35589749
- Kurmyshkina O et al. Markers of Angiogenesis, Lymphangiogenesis, and Epithelial-Mesenchymal Transition (Plasticity) in CIN and Early Invasive Carcinoma of the Cervix: Exploring Putative Molecular Mechanisms Involved in Early Tumor Invasion. Int J Mol Sci 21:N/A (2020). PubMed: 32899940
- Chen J et al. CircASH2L Promotes Ovarian Cancer Tumorigenesis, Angiogenesis, and Lymphangiogenesis by Regulating the miR-665/VEGFA Axis as a Competing Endogenous RNA. Front Cell Dev Biol 8:595585 (2020). PubMed: 33330483